European Journal of Biomedical and Pharmaceutical Sciences

ESTIMIATION OF SERUM HEPCIDIN LEVEL IN SUDANESE PATIENTS WITHS SICKLE CELL ANEMIA

*Hiyam Ahmed Mohammed Ali, Enaam A. Abdelgader and Soad Fadlallah Ali

ABSTRACT

Sickle cell disease (SCD) is general term for abnormalities of hemoglobin structure in which sickle gene is inherited from at least one parent. This genetic disorders are characterized by the production of Hb S. A cute and chronic tissue damage secondary to the blockage of blood flow produced by abnormally shaped red blood cells. Sickle cell disease (SCD) patients are characterized by chronic hemolytic anemia, increased erythropoiesis and a chronic inflammatory state with endothelial activation and enhanced red cell and leukocyte adhesion. Sickle cell patients have iron overload due to chronic blood transfusions in the treatment or prevention of the severe sickle cell-related complications such as stroke. Hepcidin It is the major hormonal regulator of iron homeostasis, synthesized by hepatocytes. It inhibits iron release from macrophages intestinal, epithelial cells and form placenta. The peptide hormone hepcidin exerts its function by binding to the trasmembrane cellular iron exporter ferroportin and inducing its internalization and degradation, resulting in decreased intestinal iron uptake and iron retention in the reticulo-endothelial (RE) macrophages. The purpose of this study was to evaluate the serum hepcidin level in Sudanese patients with sickle cell anemia. A total of 45 patients diagnosed with sickle cell anemia based on haemoglobin electrophoresis. serum was separated from participants for ELISA tests to estimate hepecidin level. A total of 45 patients diagnosed as sickle cell anemia (SS) in Sudan, their ages ranges from 5 -20 years. The hepcidin level showed, no correlation with duration of disease and frequency of blood Transfusions. There is association of hepcidin level with RBcs count, hemoglobin and PCV and insignificant correlation of serum hepcidin levels with gender, age and duration of disease.

Keywords: Serum hepcidin, Sickle cell diseases.